New trials, publications, preprints and grants on this target, month by month.
Trial
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
1 Jul 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
1 Dec 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
CDK4 maintains cytoskeletal homeostasis by restraining actomyosin contractility.
4 Nov 2026· EMBO reports· PUBMED
Trial
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
1 Nov 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
[CDK4/6 inhibitor to antibody-drug conjugates in HER2-low metastatic breast cancer: sequential therapeutic management of a case report.].
1 Nov 2026· Recenti progressi in medicina· PUBMED
Publication
Novel therapies create potential new options for patients with advanced breast cancer: First-line sacituzumab govitecan plus pembrolizumab may improve long-term outcomes for patients with advanced triple-negative breast cancer, whereas the new CDK4/6 inhibitor fovinaciclib shows promising efficacy.
1 Nov 2026· Cancer· PUBMED
Publication
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.
31 Oct 2026· Future oncology (London, England)· PUBMED
Trial
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing
30 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2- Breast Cancer via Lethal ROS and Inhibition of Metastasis.
18 Oct 2026· Cancer science· PUBMED
Publication
PLK1 inhibition by onvansertib enhances paclitaxel efficacy and overcomes resistance in HR+/HER2- breast cancer refractory to endocrine therapy and CDK4/6 inhibitors.
8 Oct 2026· Molecular cancer therapeutics· PUBMED
Publication
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-induced hepatotoxicity and its resolution: a study of seven cases.
8 Oct 2026· Histopathology· PUBMED
Publication
Lactate Dehydrogenase-to-Albumin Ratio and Glasgow Prognostic Score as Prognostic Markers in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.
29 Sept 2026· Current oncology (Toronto, Ont.)· PUBMED
Publication
Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer.
28 Sept 2026· Clinical drug investigation· PUBMED
Publication
Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines.
24 Sept 2026· International journal of molecular sciences· PUBMED
Publication
Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.
24 Sept 2026· Cancer chemotherapy and pharmacology· PUBMED
Publication
Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study.
22 Sept 2026· EClinicalMedicine· PUBMED
Publication
Integrative Systems Biology Prioritizes BCL2, ALK, and CDK4 as Therapeutic Candidates in Neuroblastoma through Multi-Centrality Network Analysis, Cross-Database Validation, Independent Docking Validation, and Confidence-Threshold Sensitivity Analysis.
21 Sept 2026· Computational biology and chemistry· PUBMED
Publication
Prognostic Value of Baseline Metabolic Tumor Volume on [18F]FDG PET/CT in Metastatic Breast Cancer Treated With CDK4/6 Inhibitors.
20 Sept 2026· Clinical breast cancer· PUBMED
Publication
Safety-guided selection of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: toxicity profiles, dose modification, and clinical risk-benefit considerations.
16 Sept 2026· Therapeutic advances in drug safety· PUBMED
Publication
Integration of MRI radiomics with immune profiling to predict response to CDK6 inhibitors in high-grade glioma.
15 Sept 2026· Frontiers in immunology· PUBMED
Publication
CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.
14 Sept 2026· Journal of the American Society of Nephrology : JASN· PUBMED
Publication
First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam.
7 Sept 2026· Frontiers in oncology· PUBMED
Publication
On-Treatment NLR Dynamics During CDK4/6 Inhibition Are Associated with Overall Survival in Metastatic Breast Cancer.
7 Sept 2026· Cancers· PUBMED
Publication
CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2.
5 Sept 2026· Medical oncology (Northwood, London, England)· PUBMED
Publication
Editor's Note: miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.
2 Sept 2026· Cancer research· PUBMED
Trial
Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer
1 Sept 2026· PHASE3 · NOT_YET_RECRUITING· CTIS
Trial
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
1 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Downregulation of circ_0001112 Enhances Myocardial Infarction Through Regulation of miR-324-5p/CDK6 Axis.
1 Sept 2026· Journal of biochemical and molecular toxicology· PUBMED
Publication
CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.
1 Sept 2026· Asia-Pacific journal of clinical oncology· PUBMED